icd-10-cm code explanation of code

1

ASCR REPORTABLE LIST (2021)

Casefinding Codes for ICD-O-3 Reportable Diseases

The following lists are intended to assist in identifying reportable neoplasms found through casefinding sources that use ICD-10-CM codes to classify the diagnoses. New Reportable/ Code Changes are to be effective for cases with Date of Diagnosis January 1, 2021.

ICD-10-CM

Code

Explanation of Code

C00.- C43.-, C4A.-, C45 - C96.-

Malignant neoplasms (excluding category C44), stated or resumed to be primary (of specified site) and certain specified histologies. Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018 C49.A- Gastrointestinal Tumors NOTE: All GIST tumors are now newly reportable for cases diagnosed 1/1/2021and forward, including GIST, NOS

D 00.- -D 09.-

In-situ neoplasms Note: Carcinoma in situ of the cervix (CIN 111-8077/2) and Prostatic lntraepithelial Carcinoma {PIN 111-8148/2) are not reportable

D18.1

Lymphangioma,any site Note: Includes Lymphangiomas of Brain, Other parts of nervous system and endocrine glands, which are reportable

D18.02 Hemangioma of intracranial structures and any site

D32.- Benign neoplasm of meninges (cerebral, spinal and unspecified)

D33.- Benign neoplasm of brain and other parts of central nervous system (includes Olfactory, Optic, Acoustic and Cranial Nerves)

D35.2- D 35.4 Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland

D37. - D41._ Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies or reportable by agreement

D42.-, D43.- tNeoplasm of uncertain or unknown behavior of meninges, brain,CNS

D44.3 - D44.5 Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland, pituitary blastoma newly reportable for cases diagnosed 1/1/2021

D45 Polycythemia vera (9950/3) D46.- D46.4 Myelodysplastic syndromes (9980, 9982,9983,9985,9986, 9989, 9991,9992)

Refractory anemia, refractory cytopenia, refractory neutropenia, refractory thrombocytopenia

D47.0 Histiocytic and mast cell tumors of uncertain behavior ICD-10-CM Coding instruction note: Excludes: malignant mast cell tumor (C96.2), mastocytosis (congenital)(cutaneous) (0852/2)

D47.1

Chronic myeloproliferative disease (9963/3,9975/3) ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_) Myelofibrosis & Secondary myelofibrosis {D75.81) Myelophthisic anemia & Myelophthisis {D61.82)

D47.3

Essential (hemorrhagic) thrombocythemia (9962/3) Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia

2

D47.4

Osteomyelofibrosis {9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia) Secondary myelofibrosis in myeloproliferative disease

D47.Z- D47.9

Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3,9970/1,9971/3,9931/3)

D49.6, D49.7 Screening Codes: Neoplasm of unspecified behavior of brain, endocrine glands and other

CNS. Acoustic Neuromas are reportable.

D63.0 Screening Codes: Anemia in neoplastic disease

D64.81 Screening Codes: Anemia due to antineoplastic chemotherapy

D72.1 Hypereosinophilic syndrome (9964/3)*

D76.1 – D76.3

Hemophagocytic syndromes. Reportable inclusion terms: Histiocytic syndromes (9751/3) Note: Hemophagocytic lymphohistiocytosis (also known as hemophagocytic syndrome) can

be caused by or associated with a number of conditions, one of which is EBV+ T- cell lymphoproliferative disease of childhood (9724/3)

D81.6, D81.7, D81.89, D81.9, D84.9

Screening Codes: Immunodeficiency, unspecified Note: Associated with lymphoproliferative disorders

D89.1 Gamma heavy chain disease; Franklin’s disease (9762/3)

J91.0 Malignant pleural effusion Note: Code first malignant neoplasm, if known

R18.0

Malignant ascites Note: Code first malignant neoplasm, if known

R85.614 Cytologic evidence of malignancy on smear of anus

R87.614 Cytologic evidence of malignancy on smear of cervix

R87.624 Cytologic evidence of malignancy on smear of vagina

Z03.89 Observation for suspected malignant neoplasm

Z12.31 Encounter for screening mammogram for malignant neoplasm of breast

Z51.0 Admission for radiotherapy

Z51.11, Z75.12 Encounter for antineoplastic chemotherapy and immunotherapy

3

Supplemental Codes

B20

Human immunodeficiency virus [HIV] disease with other diseases

B97.33, B97.34, Papillomarvirus as the cause of diseases classified elsewhere

B97.35, B97.7 Human T-cell lymphotrophic virus,( type I [HTLV-1], type II [HTLV-11],type 2 [HIV 2]) as the cause of diseases classified elsewhere

Q85.

Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable Please note:

• The central registry does NOT collect PIN III, CIN III, and CIS of the cervix.

• Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries which move from /3 to /1 will

NOT be collected as of 1/1/2001, but cases diagnosed before 1/1/2001 will continue to be submitted to the central registry.

• Basal and Squamous cell carcinoma of the skin are not reportable but tumors that originate in the

mucous membrane are reportable and include the following:

Lip C00.0 – C00.9 Anus C21.0 Labia C51.0 – C51.1 Clitoris C51.2 Vulva C51.9 Vagina C52.9 Prepuce C60.0 Penis C60.1 – C60.9 Scrotum C63.2

• All melanomas are reportable. All Merkel Cell Carcinomas are reportable. • “Early/evolving invasive and in situ melanoma” newly reportable for cases diagnosed 1/1/2021 forward • Dermatofibrosarcoma protuberans, Dermatofibrosarcoma not reportable for cases diagnosed 1/1/2021 forward

• As of 1/1/2003 cases of in situ, localized, regional, or distant neoplasm of the skin (ICD-O Topography

codes C44.0 – C44.9) with the following ICD-O Morphology codes are NOT reportable to ASCR.

M 8000 – 8004 Neoplasms, NOS M 8010 – 8045 Epithelial neoplasms M 8050 – 8082 Squamous cell neoplasms of the skin M 8090 – 8110 Basal cell neoplasms of the skin

• Pancreatic endocrine tumor, Pancreatic neuroendocrine tumor, Islet cell tumor, NOS (C25.4, 8150/3) newly reportable for cases diagnosed 1/1/2021 forward

4

The following terms are synonymous with in situ disease (Behavior code /2)

Adenocarcinoma in an adenomatous polyp with no invasion of stalk Bowen’s disease Cervical intraepithelial neoplasia or CIN III (not reportable) Clark’s level I melanoma or limited to epithelium Non-infiltrating comedocarcinoma, confined to epithelium Hutchison’s melanotic freckle NOS, intracystic non-infiltrating, intraductal, intraepithelium NOS,

intraepidermal NOS (involvement up to but no including basement membrane.) Lentigo maligna, lobular neoplasia, lobular non-infiltrating, noninvasive, no stromal involvement, Papillary

non-infiltrating or intraductal Precancerous melanosis Prostatic intraepithelial neoplasia Grade III or PIN III (not reportable) Queyrat’s erthroplasia, stage 0 Vaginal intraepithelial neoplasia Grade III or VAIN III Vulvar intraepithelial neoplasia Grade III or VIN III Laryngeal intraepithelial neoplasia, grade III (LINIII) (8077/2), C320-C329) is REPORTABLE. Squamous intraepithelial neoplasia, grade III (SINIII) (8077/2), except Cervix and Skin, is reportable.

If any invasion is present, no matter how limited – these cases must be coded to invasive behavior /3

Example: carcinoma in situ 8010/2 of vagina with microinvasion would be coded as invasive carcinoma 8010/3

• All cancer cases should be reported regardless of the patient’s state of residency at the time of diagnosis.

Cases from other states will be reported to that state but not included in Alabama statistics.

• All in situ cancer cases of the vagina, vulva, and anus are reportable to ASCR. VAIN III, VIN III, AIN III with morphology code of 8077/2

• Carcinoid tumor, NOS, of the appendix is now reportable and should be coded to 8240/3.

• Urine cytology positive for malignancy is reportable for diagnoses in 2013 and forward

Code the primary site to 689 in the absence of any other information Exception: When a subsequent biopsy of a urinary site is negative, do not report Do not implement new/additional casefindings methods to capture these cases Do not report cytology cases with ambiguous terminology

• Recode the following conditions as shown.

o Recode all cases of enteroglucogonoma, NOS, as 8152/1. Enteroglucagonoma is now a related

term for glucogonoma. o Then delete code 8157/1 Enteroglucagonoma, NOS o Recode all cases of enteroglucagonoma, malignant as 8152/3. Enteroglucagonoma, malignant is

now a related term for glucogonoma, malignant. o Then delete code 8157/3 Enteroglucagonoma, malignant

NOTE: It is important to understand that cancer registry reportability rules based on behavior code still apply. With the exception of primary intracranial and central nervous system benign and borderline tumors, the addition of a /0 or /1 coded term to ICD-O-3 does not imply that it is now reportable.

Please refer to the ICD-O 3.2 Updated Alphabetical List for all Newly Reportable and Code Changes on Pages 5 – 17 affective for cases with a Date of Diagnosis 2021 and forward.

5

ICD-O Update

Reportable for Cases with a Diagnosis Date January 1, 2021

Coding Changes for cases with a Diagnosis Date January 1, 2021

Table 7: Combined 2021 ICD-O-3.2 update (alpha)

Status abbreviations used in the update table

Status Definition BC Behavior code change (change in reportability) CC Per ICD-O-3.2, several ICD-O codes have been deleted and the histologies moved to other codes. NC/T New ICD-O code and term PT Preferred term RT Related term Syn Synonym Histology terms are per WHO. Preferred terms are indicated in BOLD font.

Applicable C codes will be noted next to the term in BOLD font.Coding instructions, if applicable, are noted in the “Comments” column.

Status ICD-O-3.2 Morphology Code

Term(s) Reportable Y/N

Comments

RT 8140/3 Acinar adenocarcinoma of prostate (C61.9) Y Syn 8744/3 Acral lentiginous melanoma, malignant (C44. _) Y PT 8744/3 Acral melanoma (C44. _) Y BC 8158/3 ACTH-producing tumor

Y Reportable for cases diagnosed

1/1/2021 forward. Not reportable prior to 1/1/2021

PT 9840/3 Acute erythroid leukemia Y CC 9687/3 Acute leukemia, Burkitt type [obs]

Y Cases diagnosed prior to 1/1/2021

use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3

CC 9687/3 Acute lymphoblastic leukemia, mature B-cell type

Y Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward use code 9687/3

NC/T 9912/3 Acute myeloid leukemia with BCR-ABL1 Y Reportable for cases diagnosed 1/1/2021 forward

NC/T 9878/3 Acute myeloid leukemia with biallelic mutations of CEBPA Y Reportable for cases diagnosed 1/1/2021 forward

NC/T 9877/3 Acute myeloid leukemia with mutated NPM1 Y Reportable for cases diagnosed 1/1/2021 forward

NC/T 9879/3 Acute myeloid leukemia with mutated RUNX1 Y Reportable for cases diagnosed 1/1/2021 forward

6

Syn 9840/3 Acute myeloid leukemia, M6 type Y Syn 8140/3 Adenocarcinoma, usual type Y PT 8390/3 Adnexal adenocarcinoma (C44. _) Y Syn 8700/3 Adrenal medullary paraganglioma (C74.1)



Syn/BC 8408/3 Aggressive digital papillary adenoma (C44. _) see comments* See comments The term “Aggressive digital papillary adenoma” has changed behavior from /1 to /3. Cases diagnosed prior to 1/1/2021 with this term are not reportable. Cases with this term diagnosed 1/1/2021 and after are reportable

Syn 9310/3 Ameloblastoma, malignant Y PT 9310/3 Ameloblastoma, metastasizing Y NC/T 9715/3 Anaplastic large cell lymphoma, ALK negative Y Reportable for cases diagnosed

1/1/2021 forward RT 8020/3 Anaplastic undifferentiated carcinoma (C73.9) Y Syn 8691/3 Aortic body paraganglioma (C75.5)



BC Syn Syn

8691/3 Aortic body tumor (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8691/3 Aorticopulmonary paraganglioma (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8249/3 Atypical carcinoid tumor Y CC 9687/3 B-ALL [obs]



RT 8090/3 Basal cell carcinoma with adnexal differentiation (C44. _) N Not reportable Syn 8833/1 Bednar tumor (C44. _) N Cases diagnosed prior to 1/1/2021,

report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.

Syn 8151/3 Beta cell adenoma (C25.4)

Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

Syn 8151/3 Beta cell tumor, malignant (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

NC/T 9819/3 B-lymphocytic leukemia/lymphoma, BCR-ABL1-like Y Reportable for cases diagnosed 1/1/2021 forward

RT 9715/3 Breast implant-associated anaplastic large cell lymphoma (C50. _) Y Reportable for cases diagnosed 1/1/2021 forward

Syn 9699/3 Bronchus associated lymphoid tissue lymphoma Y CC 9687/3 Burkitt cell leukemia (see also M-9687/3) Y Cases diagnosed prior to 1/1/2021

7


CC 9811/3 c-ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

RT 8140/3 Carcinoma of Skene, Cowper and Littre Glands Y Syn 8589/3 Carcinoma showing thymus-like element Y RT 8020/3 Carcinoma, poorly differentiated, NOS Y BC 8692/3 Carotid body paraganglioma (C75.4) Y Reportable for cases diagnosed


Syn 8692/3 Carotid body tumor (C75.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8693/3 Chemodectoma

Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8700/3 Chromaffin paraganglioma


Syn 8700/3 Chromaffin tumor


Syn 8700/3 Chromaffinoma


RT 8313/1 Clear cell adenofibroma of borderline malignancy (C56.9) N Not reportable PT 8313/1 Clear cell borderline tumor (C56.9) N Not reportable Syn 8313/1 Clear cell cystic tumor of borderline malignancy (C56.9) N Not reportable Syn 8313/1 Clear cell tumor, atypical proliferation (C56.9) N Not reportable PT 9473/3 CNS Embryonal tumor, NOS Y CC 9811/3 Common ALL



CC 9811/3 Common precursor B ALL


RT 8693/3 Composite paraganglioma Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8700/3 Composite pheochromocytoma (C74.1)


RT/BC 8500/2 Cystic hypersecretory carcinoma (C50. _) Y Cases diagnosed prior to 1/1/2021, code to 8508/3. ICD-O-3.2 now lists

8

this term under 8500 with a behavior code of 2.

RT 8020/3 Dedifferentiated carcinoma Y BC 8832/1 Dermatofibrosarcoma protuberans, NOS N Cases diagnosed prior to 1/1/2021,

report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.

Syn 8832/1 Dermatofibrosarcoma, NOS N Cases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable.

Syn 8832/3 Dermatofibrosarcoma, sarcomatous (C44. _) Y RT 9680/3 Diffuse large B-cell lymphoma, activated B-cell subtype Y RT 9680/3 Diffuse large B-cell lymphoma, germinal center B-cell subtype Y PT 9680/3 Diffuse large B-cell lymphoma, NOS Y PT 8408/3 Digital papillary adenocarcinoma (C44. _) Y

RT 8720/3 Early/Evolving invasive melanoma (C44. _) Y “Early/evolving invasive melanoma” is reportable for cases diagnosed 1/1/2021 forward

RT 8720/2 Early/Evolving melanoma in situ (C44. _) Y Early/Evolving melanoma in situ is reportable for cases diagnosed 1/1/2021 forward

Syn 8408/3 Eccrine papillary adenocarcinoma (C44. _) Y Syn 8409/3 Eccrine poroma, malignant (C44. _) Y PT 8921/3 Ectomesenchymoma Y Syn 8273/3 Embryoma Y Reportable for cases diagnosed

1/1/2021 forward RT 8509/3 Endocrine mucin-producing sweat gland carcinoma (C44. _) Y RT 8509/2 Endocrine mucin-producing sweat gland carcinoma in situ (C44. _) Y RT 8158/3 Endocrine tumor, functioning, NOS



RT 8140/3 Endolymphatic sac tumor Y BC 8380/2 Endometrioid intraepithelial neoplasia (C54.1) Y Reportable for cases diagnosed


NC/T 9749/3 Erdhiem-Chester Disease Y Reportable for cases diagnosed 1/1/2021 forward

PT 9364/3 Ewing sarcoma Y 1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases diagnosed prior to 1/1/2021 should be coded to 9260/3.

BC 8693/3 Extra-adrenal paraganglioma, NOS Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

CC 9687/3 FAB L3 [obs] Y Cases diagnosed prior to 1/1/2021 use code 9826/3 Cases diagnosed 1/1/2021 forward

9

use code 9687/3 Syn 8330/3 Follicular adenocarcinoma (C73.9) Y BC 8335/1 Follicular carcinoma, encapsulated N Cases diagnosed prior to 1/1/2021

are reportable and coded to 8335/3. Cases diagnosed 1/1/2021 and after are not reportable.

PT 8330/3 Follicular carcinoma, NOS (C73.9) Y RT 9695/3 Follicular lymphoma, duodenal type (C17.0) Y RT 9690/3 Follicular lymphoma, pediatric type Y PT 8335/1 Follicular tumor of uncertain malignant potential N Syn 8936/3 GANT



RT 8936/3 Gastrointestinal autonomic nerve tumor


RT 8936/3 Gastrointestinal pacemaker cell tumor Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 8936/3 Gastrointestinal stromal sarcoma


BC 8936/3 Gastrointestinal stromal tumor Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

Syn 9411/3 Gemistrocytic astrocytoma IDH mutant (C71. _) Y Syn 8936/3 GIST, malignant



Syn 8690/3 Glomus jugulare tumor, NOS (C75.5)


Syn 8315/3 Glycogen-rich clear cell carcinoma Y BC 8620/3 Granulosa cell tumor, adult type (C56.9) Y Granulosa cell tumor, adult type of

the ovary diagnosed prior to 1/1/2021 are not reportable. Cases diagnosed 1/1/2021 forward are now reportable.

Syn 8815/3 Hemangiopericytoma, malignant Y Cases diagnosed prior to 1/1/2021 use code 9150/3 Cases diagnosed 1/1/2021 forward use code 8815/3

PT 9738/3 HHV8-positive diffuse B-cell lymphoma Y PT 8402/3 Hidradenocarcinoma (C44. _) Y Syn 8077/2 High grade squamous intraepithelial lesion Y

BC 9725/1 Hydroa vacciniforme-like lymphoproliferative disorder N Cases diagnosed prior to 1/1/2021, report the case and code to 9725/3. Cases diagnosed 1/1/2021 forward are not reportable

10

BC 9080/1 Immature teratoma of the lung (C34. _) N Immature teratomas arising in lung are not reportable for cases diagnosed 1/1/2021 forward.

BC 9080/1 Immature teratoma of the thymus (C37.9)

N Immature teratomas arising in thymus are not reportable for cases diagnosed 1/1/2021 forward.

BC 9080/1 Immature teratoma of the thyroid (C73.9) N Immature teratomas arising in thyroid are not reportable for cases diagnosed 1/1/2021 forward.

Syn 9685/1 In situ follicular lymphoma

N In situ lymphoma is not reportable

NC 9695/1 In situ follicular neoplasm

N

In situ lymphoma is not reportable

Syn 9673/1 In situ mantle cell lymphoma N Not reportable NC/T 9673/1 In situ mantle cell neoplasm N Not reportable Syn 8337/3 Insular carcinoma (C73.9) Y BC 8151/3 Insulinoma, NOS (C25.4)


1/1/2021 forward. Not reportable prior to 1/1/2021.

RT 8580/3 Intrapulmonary thymoma (C37.9)

Y “Malignant” removed from pre-ICD-O-3.2 term

PT 8589/3 Intrathyroid thymic carcinoma (C73.9) Y RT 8150/3 Islet cell adenocarcinoma (C25.4)



RT 8150/3 Islet cell adenoma (C25.4)


RT 8150/3 Islet cell adenomatosis (C25.4)


RT 8150/3 Islet cell carcinoma (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8150/3 Islet cell tumor, NOS (C25.4)


Syn 8690/3 Jugular paraganglioma (C75.5)


Syn 8690/3 Jugulotympanic paraganglioma (C75.5) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

RT 8071/3 Keratoacanthoma Y BC 9751/1 Langerhans cell histiocytosis, NOS

Langerhans cell histiocytosis, monostotic Langerhans cell histiocytosis, polystotic

N N N

Please note, these terms are not reportable. Refer to Hematopoietic Database for reportable terms. Cases diagnosed prior to 1/1/2021, report the case and code to 9751/3.

11

Cases diagnosed 1/1/2021 forward are not reportable

Syn 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease Y RT 9698/3 Large B-cell lymphoma with IRF4 rearrangement Y RT 8693/3 Laryngeal paraganglioma



PT 8743/3 Low cumulative sun damaged melanoma (C44. _) Y BC 9718/1 Lymphoid papulosis (C44. _) N Cases diagnosed prior to 1/1/2021,

report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable

BC 9766/3 Lymphomatoid granulomatosis, grade 3 Y Reportable for cases diagnosed 1/1/2021 forward

Syn 9680/3 Malignant lymphoma, large B-cell, diffuse, NOS Y CC 9823/3 Malignant lymphoma, lymphocytic, diffuse, NOS



CC 9823/3 Malignant lymphoma, lymphocytic, NOS


CC 9823/3 Malignant lymphoma, lymphocytic, well differentiated, diffuse


CC 9823/3 Malignant lymphoma, small B lymphocytic, NOS (see also M- 9823/3)

Y

Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

CC 9823/3 Malignant lymphoma, small cell diffuse


CC 9823/3 Malignant lymphoma, small cell, NOS


CC 9823/3 Malignant lymphoma, small lymphocytic, diffuse


CC 9823/3 Malignant lymphoma, small lymphocytic, NOS Y Cases diagnosed prior to 1/1/2021 use code 9670/3 Cases diagnosed 1/1/2021 forward use code 9823/3

PT 8761/3 Malignant melanoma arising in giant congenital nevus (C44. _) Y Syn 8761/3 Malignant melanoma in giant pigmented nevus (C44. _) Y

12

Syn 8982/3 Malignant myoepithelioma Y Syn 8963/3 Malignant rhabdoid tumor Y PT 8770/3 Malignant Spitz tumor (C44. _) Y RT 8510/3 Medullary-like carcinoma Y RT 9477/3 Medulloblastoma, group 3 (C71.6) Y RT 9477/3 Medulloblastoma, group 4 (C71.6) Y RT 9475/3 Medulloblastoma, WNT-activated, anaplastic type (C71.6) Y RT 9475/3 Medulloblastoma, WNT-activated, classic (C71.6) Y RT 9475/3 Medulloblastoma, WNT-activated, large cell type (C71.6) Y Syn 8780/3 Melanoma arising in a blue nevus (C44. _) Y RT 8720/3 Melanoma, meningeal (C70. _) Y RT 8580/3 Metaplastic thymoma (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term PT 8407/3 Microcystic adnexal carcinoma (C44. _) Y BC 8690/3 Middle ear paraganglioma (C75.5) Y Reportable for cases diagnosed


Syn 8244/3 Mixed carcinoid and adenocarcinoma Y RT 8770/3 Mixed epithelioid and spindle cell melanoma Y Syn 8482/3 Mucinous adenocarcinoma, endocervical type Y RT 8470/2 Mucinous cystadenocarcinoma, non-invasive (C25. _) Y BC 8470/2 Mucinous cystic neoplasm with high grade dysplasia (C25. _) Y Syn 9699/3 Mucosa associated lymphoid tissue lymphoma Y Syn 8091/3 Multifocal superficial basal cell carcinoma (C44. _) N Not reportable BC 9505/0 Multinodular and vascolating neuronal tumor (MVNT) (C71.2) Y WHO has not yet assigned a specific

ICD-O code for this neoplasm. In the interest of collecting these tumors, 9505/0 has been assigned by neuropathology experts.

Syn 9732/3 Multiple myeloma (C42.1) Y Syn 9986/3 Myelodysplastic syndrome with 5q deletion (5q-) syndrome Y PT 9986/3 Myelodysplastic syndrome with isolated del (5q) Y PT 9985/3 Myelodysplastic syndrome with multilineage dysplasia Y PT 9993/3 Myelodysplastic syndrome with ring sider0blasts and multilineage dysplasia Y PT

9982/3 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia Y

PT 9980/3 Myelodysplastic syndrome with single lineage dysplasia Y NC/T 9968/3 Myeloid/lymphoid neoplasm with PCM1-JAK2 Y Reportable for cases diagnosed

1/1/2021 forward PT 8982/3 Myoepithelial carcinoma Y RT 8150/3 Nesidioblastoma (C25.4)



PT 8249/3

Neuroendocrine tumor, grade 2 Y Y Y

RT 8249/3 Neuroendocrine tumor, grade 3 Y Removed 9540/1 Neurofibromatosis, NOS N WHO has removed

13

from ICD-O-3.2

neurofibromatosis from ICD-O-3.2. This disease is not reportable for cases diagnosed 1/1/2018 forward per Solid Tumor Rules

RT 8720/3 Nevoid melanoma (C44. _) Y

Syn 8402/3 Nodular hidradenoma, malignant (C44. _) Y RT 8693/3 Nonchromaffin paraganglioma, NOS



NC/T 8349/1 Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9)

N This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward.

NC/T 8349/1 Non-invasive FTP N This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward

Syn 8150/3 Pancreatic endocrine tumor, nonfunctioning (C25.4)


Syn 8150/3 Pancreatic endocrine tumor, NOS (C25.4)


BC 8150/3 Pancreatic neuroendocrine tumor, nonfunctioning (C25.4) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021.

PT 8342/3 Papillary carcinoma, oncocytic variant (C73.9) Y Syn 8342/3 Papillary carcinoma, oxyphilic cell (C73.9) Y CC 8470/3 Papillary mucinous cystadenocarcinoma (C56.9) Y Cases diagnosed prior to 1/1/2021


CC 8470/3 Papillary pseudomucinous cystadenocarcinoma (C56.9) Y Cases diagnosed prior to 1/1/2021 use code 8471/3 Cases diagnosed 1/1/2021 forward use code 8470/3

Syn 8441/3 Papillary serous adenocarcinoma (C56.9)

Y Cases diagnosed prior to 1/1/2021 use code 8460/3

Syn 8441/3 Papillary serous cystadenocarcinoma (56.9)

Y Cases diagnosed prior to 1/1/2021 use code 8460/3

Syn 8130/1 Papillary transitional cell neoplasm of low-malignant potential (C67. _) N Not reportable PT 8130/1 Papillary urothelial neoplasm of low-malignant potential (C67. _) N Not reportable RT 8083/3 Papillary-basaloid carcinoma Y BC 8681/3 Paraganglioma, NOS (C75.5) Y Reportable for cases diagnosed

1/1/2021 forward. Not reportable

14

prior to 1/1/2021 BC 8682/3 Parasympathetic paraganglioma (C75.5) Reportable for cases diagnosed


RT 8140/3 Parathyroid tumor (C75.0) Y Syn 8700/3 Pheochromoblastoma (C74.1) Y Reportable for cases diagnosed


BC 8700/3 Pheochromocytoma, NOS (C74.1) Y Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021

BC Syn

8833/1 Pigmented dermatofibrosarcoma protuberans (C44. _) N Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable.

PT Syn

8110/3 Pilomatrical carcinoma (C44. _) Pilomatrix carcinoma (C44. _)

N N

Not reportable Not reportable

NC/T 8273/3 Pituitary blastoma (C75.1) Y Reportable for cases diagnosed 1/1/2021 forward

PT 9732/3 Plasma cell myeloma (C42.1) Y Syn 8802/3 Pleomorphic cell sarcoma, undifferentiated Y RT 8802/3 Pleomorphic dermal sarcoma (C44. _) Y Syn 8802/3 Pleomorphic sarcoma Y BC 9971/3 Polymorphic post-transplant lymphoproliferative disorder N Cases diagnosed prior to 1/1/2021,


Syn 8246/3 Poorly differentiated neuroendocrine neoplasm Y PT 8337/3 Poorly differentiated thyroid carcinoma (C73.9) Y PT 8409/3 Porocarcinoma (C44. _) Y BC 9971/1 Post-transplant lymphoproliferative disorder, NOS N Cases diagnosed prior to 1/1/2021,


CC 9811/3 Pre-B ALL


CC 9811/3 Precursor B-cell lymphoblastic leukemia (see also M-9728/3)


CC 9811/3 Precursor B-cell lymphoblastic lymphoma (see also M-9836/3) Y Cases diagnosed prior to 1/1/2021 use code 9728/3 Cases diagnosed 1/1/2021 forward use code 9811/3

CC 9837/3 Precursor T-cell lymphoblastic lymphoma (see also M-9837/3) Y Cases diagnosed prior to 1/1/2021 use code 9729/3 Cases diagnosed 1/1/2021 forward

15

use code 9837/3 CC 9811/3 Pre-pre-B ALL



RT 9699/3 Primary choroidal lymphoma (C69.3) Y BC 9718/1 Primary cutaneous CD30+ T cell lymphoproliferative

disorder (C44. _) N

Cases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable

BC 9709/1 Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. _) N Cases diagnosed prior to 1/1/2021, report the case and code to 9709/3. Cases diagnosed 1/1/2021 forward are not reportable

CC 9811/3 Pro-B ALL Y Cases diagnosed prior to 1/1/2021 use code 9836/3 Cases diagnosed 1/1/2021 forward use code 9811/3

RT 8074/3 Pseudovascular squamous cell carcinoma Y BC 9971/3 PTLD, NOS

N Cases diagnosed prior to 1/1/2021,


Syn 9980/3 Refractory anemia Syn 9982/3 Refractory anemia with excess blasts, NOS Y RT 9985/3 Refractory cytopenia of childhood Y Syn 9985/3 Refractory cytopenia with multilineage dysplasia Y CC 9980/3 Refractory neutropenia Y Cases diagnosed prior to 1/1/2021


CC 9980/3 Refractory thrombocytopenia Y Cases diagnosed prior to 1/1/2021 use code 9992/3 Cases diagnosed 1/1/2021 forward use code 9980/3

PT 8963/3 Rhabdoid tumor, NOS Y Syn 8921/3 Rhabdomyosarcoma with ganglionic differentiation Y Syn 8912/3 Rhabdomyosarcoma, spindle-cell/sclerosing type Y Syn 8407/3 Sclerosing sweat duct carcinoma (C44. _) Y RT 8580/3 Sclerosing thymoma (C37.9)

Y “Malignant” removed from pre-ICD-

O-3.2 term Syn 8410/3 Sebaceous adenocarcinoma (C44. _) Y PT 8410/3 Sebaceous carcinoma (C44. _) Y PT 9391/3 Sellar ependymoma (C75.1) Y PT 8441/3 Serous cystadenocarcinoma, NOS (56.9) Y Cases diagnosed prior to 1/1/2021

use code 8460/3 Syn 8441/3 Serous papillary adenocarcinoma, NOS (C56.9)


use code 8460/3 Syn 8441/3 Serous surface papillary carcinoma (C56.9) Y Cases diagnosed prior to 1/1/2021

16

use code 8460/3 Syn 8390/3 Skin appendage carcinoma (C44. _) Y Syn 8230/3 Solid adenocarcinoma, NOS Y RT 8452/3 Solid pseudopapillary carcinoma Y PT 8452/3 Solid pseudopapillary neoplasm of the pancreas (C25. _) Y RT 8120/3 Squamotransitional carcinoma Y Syn 8077/2 Squamous dysplasia, high grade Y Syn 8077/2 Squamous intraepithelial neoplasm, grade II See comments The term “squamous intraepithelial

neoplasm, grade II” is NOT reportable for C53. _

PT 8091/3 Superficial basal cell carcinoma (C44. _) N Not reportable RT 8743/3 Superficial spreading melanoma (C44. _) Y RT 8200/3 Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9) Y RT 8585/3 Thymoma, atypical (C37.9)


O-3.2 term RT 8585/3 Thymoma, epithelial (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term RT 8583/3 Thymoma, lymphocyte-rich (C37.9)


O-3.2 term RT 8583/3 Thymoma, lymphocytic (C37.9)


O-3.2 term RT 8581/3 Thymoma, medullary (C37.9)


O-3.2 term RT 8582/3 Thymoma, mixed type (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term PT 8580/3 Thymoma, NOS (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term RT 8583/3 Thymoma, organoid (C37.9)


O-3.2 term RT 8583/3 Thymoma, predominantly cortical (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term RT 8581/3 Thymoma, spindle cell (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term PT 8581/3 Thymoma, type A (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term PT 8582/3 Thymoma, type AB (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term PT 8583/3 Thymoma, type B1 (C37.9) Y “Malignant” removed from pre-ICD-

O-3.2 term PT RT

8584/3 Thymoma, type B2 (C37.9) Thymoma, cortical (C37.9)

Y Y

“Malignant” removed from pre-ICD-O-3.2 term

PT 8585/3 Thymoma, type B3 (C37.9) Y “Malignant” removed from pre-ICD-O-3.2 term

Syn 8131/3 Transitional cell carcinoma, micropapillary Y Syn 8122/3 Transitional cell carcinoma, spindle cell PT 8122/3 Urothelial carcinoma, sarcomatoid Y Syn 8122/3 Urothelial carcinoma, spindle cell Y RT 8693/3 Vagal paraganglioma


1/1/2021 forward. Not reportable

17

prior to 1/1/2021 RT 9680/3 Vitreoretinal lymphoma (C69. _) Y RT 8054/3 Warty-basaloid carcinoma Y

icd-10-cm code explanation of code

Documents